SCHEMBL3582379

SCHEMBL3582379

Cc1ccccc1C(=O)Nc1cccc(C(=O)c2ccc3c(c2)NC(=O)/C3=C\Nc2ccc(CCCC(=O)O)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KCNK3 O14649 2/20 0.41
KCNK9 Q9NPC2 2/20 0.41
RAB9A P51151 2/20 0.40
NTRK1 P04629 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
FFAR1 O14842 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
FLT3 P36888 2/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
F2R P25116 1/20 0.37
TLK2 Q86UE8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3582381 1.00 MEN1 (0.43) MEN1KMT2AKCNK3KCNK9RAB9A
SCHEMBL3577313 0.88 PKM (0.38) MEN1KMT2ARAB9ANTRK1PKM
SCHEMBL3577312 0.88 PKM (0.38) MEN1KMT2ARAB9ANTRK1PKM
SCHEMBL3575229 0.85 KDR (0.44) KMT2ANTRK1POLBFLT3FLT4
SCHEMBL3575231 0.85 KDR (0.44) KMT2ANTRK1POLBFLT3FLT4
SCHEMBL3567190 0.84 MAPT (0.46) MEN1KMT2AKCNK3KCNK9RAB9A
SCHEMBL3567188 0.84 MAPT (0.46) MEN1KMT2AKCNK3KCNK9RAB9A
SCHEMBL3580625 0.84 KDR (0.46) KMT2ANTRK1MAPTFLT3KDR
SCHEMBL3580624 0.84 KDR (0.46) KMT2ANTRK1MAPTFLT3KDR
SCHEMBL3571497 0.83 AURKB (0.37) NTRK1FLT3FLT4KDRTLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 MEN1 3831/4885KMT2A 1670/4885KCNK3 1769/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 MEN1 2293/4885KMT2A 1569/4885KCNK3 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.